Cell Death Discovery (Oct 2023)

The monosialoganglioside GM1a protects against complement attack

  • Henri Wedekind,
  • Julia Beimdiek,
  • Charlotte Rossdam,
  • Elina Kats,
  • Vanessa Wittek,
  • Lisa Schumann,
  • Inga Sörensen-Zender,
  • Arno Fenske,
  • Birgit Weinhold,
  • Roland Schmitt,
  • Andreas Tiede,
  • Falk F. R. Büttner,
  • Anja Münster-Kühnel,
  • Markus Abeln

DOI
https://doi.org/10.1038/s41420-023-01686-6
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 8

Abstract

Read online

Abstract The complement system is a part of the innate immune system in the fluid phase and efficiently eliminates pathogens. However, its activation requires tight regulation on the host cell surface in order not to compromise cellular viability. Previously, we showed that loss of placental cell surface sialylation in mice in vivo leads to a maternal complement attack at the fetal-maternal interface, ultimately resulting in loss of pregnancy. To gain insight into the regulatory function of sialylation in complement activation, we here generated trophoblast stem cells (TSC) devoid of sialylation, which also revealed complement sensitivity and cell death in vitro. Glycolipid-analysis by multiplexed capillary gel electrophoresis coupled to laser-induced fluorescence detection (xCGE-LIF) allowed us to identify the monosialoganglioside GM1a as a key element of cell surface complement regulation. Exogenously administered GM1a integrated into the plasma membrane of trophoblasts, substantially increased binding of complement factor H (FH) and was sufficient to protect the cells from complement attack and cell death. GM1a treatment also rescued human endothelial cells and erythrocytes from complement attack in a concentration dependent manner. Furthermore, GM1a significantly reduced complement mediated hemolysis of erythrocytes from a patient with Paroxysmal nocturnal hemoglobinuria (PNH). This study demonstrates the complement regulatory potential of exogenously administered gangliosides and paves the way for sialoglycotherapeutics as a novel substance class for membrane-targeted complement regulators.